Sale of Ordinary Shares in The Beauty Tech Group

TBTG’s CEO and CTO sold 1.4% of shares at £4.00, with a 90-day lock-up.

What the company is saying

The Beauty Tech Group plc discloses that CEO Laurence Newman and CTO Andrew Showman have each sold 750,000 ordinary shares, totaling 1,500,000 shares or 1.4% of the company’s issued share capital. The company frames the transaction as the first director sale since the October 2025 IPO and states it is intended to diversify the executives’ asset base. The board highlights that the sale price of 400 pence per share does not exceed the price set in the reverse accelerated bookbuild buyback (RABB) announced on 1 October 2026, emphasizing procedural fairness. Both executives retain significant holdings after the sale: Newman with 4,293,224 shares (3.9%) and Showman with 4,513,262 shares (4.1%). The announcement stresses that the sale represents less than 15% of each executive’s personal holding and that both have agreed not to sell further shares for 90 days. The tone is neutral and factual, with no promotional language or forward-looking performance claims.

What the data suggests

The transaction involved the disposal of 1,500,000 ordinary shares at 400 pence per share, executed on 9 October 2026 on the London Stock Exchange. This represents 1.4% of the company’s issued share capital and less than 15% of each executive’s individual holding. After the sale, Laurence Newman holds 4,293,224 shares (3.9%) and Andrew Showman holds 4,513,262 shares (4.1%). The nominal value per share is 10 pence. The sale is explicitly linked to the RABB price cap, ensuring no preferential treatment. Both executives are subject to a 90-day lock-up on further disposals. No operational, financial performance, or strategic data is disclosed beyond the share sale mechanics. The figures are internally consistent and fully supported by the regulatory disclosure.

Analysis

The announcement is a factual disclosure of a director share sale, providing specific details on the number of shares sold, price, resulting holdings, and a 90-day lock-up period. There is no promotional or exaggerated language, and the tone remains strictly informational. Only one minor forward-looking statement is present (the 90-day lock-up), which is standard in such transactions and not aspirational. No claims are made about future company performance, operational milestones, or financial projections. There is no mention of capital outlay, investment programs, or long-term benefits, and the transaction is already completed. The data fully supports the narrative, with no evidence of narrative inflation or overstatement.

Risk flags

• ●Director share sales can signal reduced confidence or personal liquidity needs, which some investors may interpret as a negative, though the company frames this as asset diversification and both executives retain substantial holdings.
• ●The transaction coincides with a reverse accelerated bookbuild buyback, raising potential concerns about timing and perceived alignment with minority shareholders, though the board states the sale price does not exceed the RABB level.
• ●The 90-day lock-up provides only short-term assurance against further director disposals, after which additional sales could occur, potentially increasing market supply and affecting sentiment.

Bottom line

This is a routine director share sale by TBTG’s CEO and CTO, each selling 750,000 shares at £4.00, totaling 1.4% of the company’s issued share capital. Both executives retain large stakes and have agreed to a 90-day lock-up, but the sale’s proximity to the company’s buyback may prompt questions about timing and alignment. No operational or financial performance data is provided, so the announcement does not alter the company’s investment case or outlook. The most important takeaway is that while director sales can attract scrutiny, the scale is modest relative to their holdings and is framed as diversification. Investors should monitor for further director dealings after the lock-up expires.

Announcement summary

(LSE:TBTG) The Beauty Tech Group plc announced that Laurence Newman, CEO, and Andrew Showman, CTO, have each instructed the sale of 750,000 ordinary shares of 10 pence each in the capital of the Company, totaling 1,500,000 shares (the 'Sale Shares'). The aggregate number of Sale Shares represents approximately 1.4% of the Company’s issued share capital and less than 15% of the individual Selling Shareholders’ respective holdings. This transaction marks the first sale of shares by the Selling Shareholders since the Company’s IPO in October 2025 and is intended to diversify their asset base. Following the transaction, Laurence Newman will hold 4,293,224 ordinary shares of 10 pence each, representing approximately 3.9% of TBTG’s issued share capital. Andrew Showman will hold 4,513,262 ordinary shares of 10 pence each, representing approximately 4.1% of TBTG’s issued share capital. The Board recognized the timing of the transaction relative to the reverse accelerated bookbuild buyback (RABB) announced on 1 October 2026 and concluded that, to ensure equal treatment for shareholders, the Selling Shareholders be authorized to undertake the transaction at a price not more than the RABB. The Sale Shares have been priced at 400 pence per share. The Selling Shareholders have undertaken to the Company and Berenberg not to dispose of any further ordinary shares in TBTG for a period of 90 days following completion of the transaction. The transaction took place on 09 October 2026 on the London Stock Exchange (XLON). The ISIN for the ordinary shares is GB00BTWSXB68. Berenberg acted on the instructions of the Selling Shareholders’ authorized agents in connection with the transaction. The person responsible for arranging the release of this announcement on behalf of the Company is Sarah Clayton, General Counsel and Company Secretary.

Disagree with this article?